Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of NIO752 in progressive supranuclear palsy followed by open-label extension
jRCT2031260029Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Jul 2026
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in progressive supranuclear palsy (PSP) comparing NIO752 solution with Placebo in solution (2 arms). Primary endpoint: Change from baseline in the rPSPRS-10 score. Started Jul 2026; status: recruiting.
02
Drugs
NIO752
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on jRCT2031260029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260029.